|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||75.10 - 81.68|
|52-week range||75.10 - 19,293.00|
|Beta (5Y monthly)||0.44|
|PE ratio (TTM)||14.84|
|Forward dividend & yield||1.30 (1.66%)|
|Ex-dividend date||29 Apr 2022|
|1y target est||N/A|
If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB SA (UCBJF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
UCB SA (UCBJF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.